FIELD: biotechnology.
SUBSTANCE: disclosed is a variant antigen-binding domain which contains at least one mutation in the VH domain compared to a reference antibody and which exhibits increased affinity for TRBC2 compared to said reference antibody. Also disclosed is an antibody, a chimeric antigen receptor (CAR) and a bispecific T-cell activator (BiTE), a cell which contains said CAR, and conjugate, containing said variant antigen-binding domain or said antibody. In addition, there are presented versions of application in medicine, methods of diagnostics and methods of personalized medicine, in which the products according to the present invention are used.
EFFECT: group of inventions can be used to treat a T-cell malignant neoplasm selected from T-cell lymphoma or leukemia in a subject.
42 cl, 1 tbl, 9 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN-BINDING DOMAINS TO CONSTANT REGION OF β T-CELL RECEPTOR | 2015 |
|
RU2830064C2 |
| CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN-BINDING DOMAINS TO THE T-CELL RECEPTOR β- CONSTANT REGION | 2015 |
|
RU2744046C2 |
| ANTI-TRBC1 ANTIGEN-BINDING DOMAIN | 2018 |
|
RU2791327C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| CD3-SPECIFIC BINDING MOLECULES | 2020 |
|
RU2826453C2 |
| KIR3DL3 INHIBITORY RECEPTOR OF IMMUNE SYSTEM AND USE THEREOF | 2020 |
|
RU2827900C1 |
| ANTIBODIES SPECIFIC TO FLT3 AND THEIR APPLICATIONS | 2018 |
|
RU2758513C2 |
| CELL | 2015 |
|
RU2768019C2 |
| ANTI-ROR1/ANTI-CD3 BISPECIFIC BINDING MOLECULES | 2020 |
|
RU2831608C2 |
| MULTIVALENT Fv-ANTIBODIES | 2016 |
|
RU2785766C2 |
